Colorectal Cancer Clinical Trials in New York, NY

Colorectal Cancer Clinical Trials in New York, NY

View the best 10 colorectal cancer medical studies in New York, New York. Access promising new therapies by applying to a New York-based Colorectal Cancer clinical trial.

Trials in New York, New York

Here are the top 10 medical studies for colorectal cancer in New York, New York

Image of Massachusetts General Hospital in Boston, United States.

JDQ443

KRAS G12C Inhibitor

Recruiting1 awardPhase 1 & 2
This trial tests JDQ443, a new drug, combined with other treatments for patients with advanced cancers having the KRAS G12C mutation. The drug aims to stop cancer growth by targeting a specific genetic fault.
Image of Roswell Park Cancer Institute in Buffalo, United States.

Cisplatin

Alkylating agents

Recruiting1 awardPhase 1 & 2
This trial studies a method called pulmonary suffusion, which delivers chemotherapy directly to lung tissues. It targets patients with sarcoma or colorectal cancer that has spread to the lungs. The goal is to kill cancer cells more effectively and reduce side effects by focusing treatment on the lungs.
Image of Kaleida Health, University of Buffalo in Buffalo, United States.

ActivSightTM

Procedure

Recruiting1 award
This trial is a prospective, single-center, feasibility study with two sequential cohorts.
Image of USC Norris Comprehensive Cancer Center in Los Angeles, United States.

PC14586 +1 More

Small Molecule

Recruiting1 awardPhase 1 & 2
This trial is testing a new oral drug, PC14586 (rezatapopt), alone and with pembrolizumab, in patients with advanced cancers that have a specific genetic mutation. The drug aims to fix a mutated protein to help control cancer growth. The study will determine the best dose and evaluate the drug's safety and effectiveness.
Image of Henry Ford Hospital in Detroit, United States.

Physical Activity Program +1 More

Behavioral Intervention

Recruiting1 award26 criteria
This trial is studying a physical activity program given together with health education materials to see how well it works compared with giving health education materials alone for patients who have undergone treatment for high-risk stage II or stage III colon cancer.
Image of Pacific Cancer Care ( Site 0031) in Monterey, United States.

Pembrolizumab

PD-1 Inhibitor

Recruiting2 awardsPhase 3
This trial is testing whether a new combination therapy of lenvatinib and pembrolizumab is better than the standard of care for metastatic colorectal cancer in terms of overall survival.
Image of Cross Cancer Institue in Edmonton, Canada.

BOLD-100

Small Molecule

Recruiting1 awardPhase 1 & 2
This trial will test the safety of a new ruthenium-based drug, BOLD-100, when combined with a standard chemotherapy regimen. The drug will be given intravenously, and the trial will first assess safety in a small group of patients before expanding to a larger group.
Image of City of Hope ( Site 0002) in Duarte, United States.

Pembrolizumab +1 More

Monoclonal Antibodies

Recruiting1 awardPhase 2
This trial will test a combination of two drugs to see if it is safe and effective for treating various types of cancer.
Image of University of Alabama at Birmingham - The Kirklin Clinic in Birmingham, United States.

Amivantamab +4 More

Monoclonal Antibodies

Recruiting1 awardPhase 1 & 2
This trial is testing a new medicine called amivantamab on patients with advanced colorectal cancer. The medicine helps the immune system find and destroy cancer cells. Researchers want to see how well it works alone and with standard chemotherapy.
Image of University Health Network, Toronto General Hospital in Toronto, Canada.

IVLP in single lung

Recruiting1 awardPhase 1
This trial is testing a new method of delivering chemotherapy directly into the lungs during surgery to treat patients with colorectal cancer that has spread to the lungs. The goal is to kill cancer cells in the lung while minimizing side effects to other organs. The study will determine the safest dose of the chemotherapy drug oxaliplatin when delivered using this method.

Phase 3 Trials

Trials With No Placebo

Frequently Asked Questions

Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the 'trial drug' — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
Is there any support for travel costs?
Many of the teams running clinical trials will cover the cost of transportation to-and-from their care center.
Will I know what medication I am taking?
This depends on the specific study. If you're worried about receiving a placebo, you can actively filter out these trials using our search.
How long do clinical trials last?
Some trials will only require a single visit, while others will continue until your disease returns. It's fairly common for a trial to last somewhere between 1 and 6 months.
Do you verify all the trials on your website?
All of the trials listed on Power have been formally registered with the US Food and Drug Administration. Beyond this, some trials on Power have been formally 'verified' if the team behind the trial has completed an additional level of verification with our team.
How quickly will I hear back from a clinical trial?
Sadly, this response time can take anywhere from 6 hours to 2 weeks. We're working hard to speed up how quickly you hear back — in general, verified trials respond to patients within a few days.